Cresset Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-1,675
| Closed | -$461K | – | 1664 |
|
|
2024
Q3 | $461K | Buy |
1,675
+296
| +21% | +$81.4K | ﹤0.01% | 1536 |
|
|
2024
Q2 | $335K | Buy |
+1,379
| New | +$335K | ﹤0.01% | 1621 |
|
|
2024
Q1 | – | Sell |
-1,616
| Closed | -$309K | – | 1875 |
|
|
2023
Q4 | $309K | Buy |
+1,616
| New | +$309K | ﹤0.01% | 1452 |
|
|
2022
Q1 | – | Sell |
-3,852
| Closed | -$654K | – | 989 |
|
|
2021
Q4 | $654K | Buy |
3,852
+1,402
| +57% | +$238K | 0.01% | 600 |
|
|
2021
Q3 | $463K | Buy |
2,450
+598
| +32% | +$113K | 0.01% | 653 |
|
|
2021
Q2 | $314K | Buy |
+1,852
| New | +$314K | ﹤0.01% | 743 |
|
|
2019
Q2 | – | Sell |
-62
| Closed | -$6K | – | 519 |
|
|
2019
Q1 | $6K | Buy |
62
+8
| +15% | +$774 | ﹤0.01% | 1287 |
|
|
2018
Q4 | $4K | Buy |
+54
| New | +$4K | ﹤0.01% | 1066 |
|